This is a randomized, blinded, peer-controlled study. There will be 3 treatment groups, screened subjects were randomized in a 1:1:1 ratio to receive three batches of the DTcP trial vaccine, and completed the primary immunization according to the procedure of one dose each at 2, 4, and 6 months of age.
Who can participate
Age range60 Days – 89 Days
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 2 months of age (60\~89 days), willing to provide identification documents;
* The legal guardian or delegate has given informed consent, voluntarily signed the informed consent form, and can comply with the requirements of the clinical research protocol.
Exclusion Criteria:
First dose exclusion criteria
* Persons who have received a vaccine containing the DPT classified vaccine;
* Premature labor (delivery before 37th week of gestation), low birth weight 60 (birth weight \<2500g);
* Those with abnormal labor and delivery, history of asphyxia rescue, history of neurological damage;
* Who have had one of the pertussis, diphtheria or tetanus diseases;
* Who have had household contact with an individual diagnosed with pertussis, diphtheria, or tetanus disease in the past 30 days;
* Have a history of allergy to vaccines or vaccine components and severe side reactions to vaccines, such as hives, dyspnea, angioneurotic edema, and other allergic reactions;
* Persons with a history of seizures, convulsions, convulsions, or cerebral palsy; or a history or family history of psychiatric illness; or other progressive neurologic disorders;
* Have been diagnosed with an immunodeficiency, Human Immunodeficiency Virus (HIV) infection, lymphoma, leukemia, Systemic Lupus Erythematosus (SLE), Juvenile Rheumatoid Arthritis ( Juvenile Rheumatoid Arthritis (JRA) or other autoimmune diseases;
* Any condition resulting in absence of spleen, defective spleen function;
* Known…
What they're measuring
1
Geometric Mean Concentration (GMC) of serum anti-PT, FHA, PRN, DT, and TT antibodies in 2-month-old subjects with three different batches of the trial vaccine.